Cellular Dynamics International is one of 10 biomedicine companies included in Technology Review’s 50 Most Innovative Companies (TR50) for 2012 [1].
AssureRx Health Launches Personalized Medicine Test for ADHD
May 8, 2012 | by
Mason, Ohio-based AssureRx Health announced this week that it has launched a personalized medicine test for attention deficit hyperactivity disorder (ADHD). The new pharmacogenomic test — GeneSightRx ADHD — analyzes variations in three genes that influence how a patient might metabolize certain medications used to treat ADHD in children and adults.
Biomarker Bulletin: January 30, 2012
January 30, 2012 | by
Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at BiomarkerCommons.org. Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.
- Selventa Receives Patent for Method to Identify Biomarker Profiles
Selventa, a biomarker discovery company that enables personalized healthcare through the stratification of patients based on disease-driving mechanisms, recently announced a US patent that relates methods and techniques that facilitate discovery of biomarkers, thus aiding in the development of predictive and prognostic diagnostic tests for therapeutics targeting complex multi-factorial diseases.
- Biomarker Discovery: Moving Diagnostics to the Forefront of Medical Research
Increasing emphasis is being placed on biomarker discovery as the key to advancing personalized medicine.
- FDA Clears Critical Diagnostics Presage ST2 Assay for Patients with Heart Failure
Critical Diagnostics is a U.S.-based biomarker company focused on optimizing patient care in cardiovascular diseases, such as heart failure.
- SciClips Launches Cancer Biomarker Database
The success of personalized cancer therapeutics relies on the development of companion diagnostic assays that can identify the most appropriate cancer patient, tumor type and disease state. To address this need, SciClips, a Wisconsin-based open innovation platform company that enables scientists and researchers to collaborate and share research and ideas, recently launched a cancer (oncology) biomarker database.
- The Bill & Melinda Gates Foundation to Fund Biomarkers of Gut Function for Global Health
The Bill & Melinda Gates Foundation is currently seeking letters of inquiry for the grant program Biomarkers of Gastrointestinal (Gut) Function and Health.
Is My Cancer Different? A Personalized Medicine Campaign
December 29, 2011 | by
The Is My Cancer Different? campaign urges patients to ask their doctors a crucial question — is my cancer different? — and provides powerful information on why, when and how it could matter to their treatment choices.
Presented in video format and featuring cancer survivors, physicians, scientists, advocates and Ronnie Andrews, the president of Clarient, the personalized medicine campaign covers what indivdualized cancer treatment means, what makes a patient’s cancer different, treatment decisions, expert insights and more.
The GE Healthymagination Initiative Against Cancer
November 18, 2011 | by
In September, GE and leading healthcare and financial partners launched a new healthymagination initiative focused on accelerating cancer innovation and improving care for 10 million cancer patients around the world by 2020 [1]. The plan was announced in New York by GE’s CEO and Chairman Jeff Immelt to an audience of prominent cancer scientists and researchers, doctors, financial partners and employees of GE Healthcare. The company’s comprehensive initiative combines the strength of GE’s portfolio of integrated cancer technologies with collaboration between GE and new partners and data sources to help clinicians provide better, more personalized care.
